Madrigal Pharmaceuticals, Inc.
MDGL
$425.85
-$9.77-2.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 11.77% | 34.99% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 11.77% | 34.99% | |||
| Cost of Revenue | 34.91% | 99.91% | |||
| Gross Profit | 10.21% | 32.10% | |||
| SG&A Expenses | 14.76% | 6.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.12% | 54.32% | |||
| Operating Income | 47.70% | -141.46% | |||
| Income Before Tax | 48.70% | -170.07% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 48.70% | -170.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 48.70% | -170.07% | |||
| EBIT | 47.70% | -141.46% | |||
| EBITDA | 47.88% | -142.64% | |||
| EPS Basic | 49.48% | -166.77% | |||
| Normalized Basic EPS | 48.22% | -160.27% | |||
| EPS Diluted | 49.48% | -166.77% | |||
| Normalized Diluted EPS | 48.22% | -160.27% | |||
| Average Basic Shares Outstanding | 1.54% | 1.24% | |||
| Average Diluted Shares Outstanding | 1.54% | 1.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||